Over the last few decades, volatolomics has been keeping attention of the medical community as it has often been reported as a low invasiveness approach for potential diagnosis of various diseases. The idea of mapping volatile organic compounds (VOCs) emitted from biological specimens is not new but has barely reached any routinely validated status in hospitals.
New generations of instruments such as selected-Ion Flow-Tube Mass Spectrometer (SIFT-MS) or comprehensive two-dimensional gas chromatography time-of-flight high resolution mass spectrometry (GC×GC-HRTOFMS) are enhancing the confidence and reproducibility in biomarker identification. Properly developed and validated data processing statistical tools further reinforce and estimate the related diagnosis capacity of such analytical strategies. Is that enough to now consider volatolomics at the medical level for early diagnosis or monitoring response to treatment, or even for personalized medicine?
Jean-François Focant, University of Liège
Dit webinar vindt plaats op dinsdag 1 december om 10.00 uur.